Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure

References

• Theisen-Toupal J. Hypokalemia and hyperkalemia. Hosp Med Clin 2015;4:34-50
   Web of Science ®Google Scholar
• Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician 2015;92:487-95
   PubMed Web of Science ®Google Scholar
• Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci 2014;10:251-7
   PubMed Web of Science ®Google Scholar
• Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012;109:1510-3
   PubMed Web of Science ®Google Scholar
• Kovesdy CP. Epidemiology of hyperkalemia: an update. Kidney Int Suppl 2016;6:3-6
   PubMed Web of Science ®Google Scholar
• Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 2011;26:377-84
   PubMed Web of Science ®Google Scholar
• Silverberg D, Wexler D, Blum M, et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004;13:163-70
   PubMed Web of Science ®Google Scholar
• Pearse SG, Cowie MR. Heart failure: classification and pathophysiology. Medicine 2014;42:556-61
   Google Scholar
• Núñez J, Bayés-Genís A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 2018;137:1320-30
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 2017;46:213-21
   PubMed Web of Science ®Google Scholar
• Krogager ML, Eggers-Kaas L, Aasbjerg K, et al. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother 2015;1:245-51
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51
   PubMed Web of Science ®Google Scholar
• Aldahl M, Jensen ASC, Davidsen L, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017;38:2890-6
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-18
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2129-200
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [Internet]. Chronic heart failure in adults: management. Clinical guideline [CG108]. London, UK: NICE; 2010. Available at: https://www.nice.org.uk/guidance/cg108 [Last accessed 28 July 2017]
   Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-84
   PubMed Web of Science ®Google Scholar
• Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl 2016;6:20-8
   Web of Science ®Google Scholar
• Orsborne C, Chaggar PS, Shaw SM, et al. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J 2017;93:29-37
   PubMed Web of Science ®Google Scholar
• Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 2009;6:272-80
   PubMedGoogle Scholar
• Queen Mary University of London Clinical Effectiveness Group [Internet]. Summary guidelines: Heart Failure update. London, UK:. QMUL; 2015. Available at: https://www.qmul.ac.uk/blizard/ceg/media/blizard/documents/ceg-documents/Heart-Failure-Update,-Nov-2015.pdf [Last accessed 25 October 2017]
   Google Scholar
• Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38:1883-90
   PubMed Web of Science ®Google Scholar
• Komajda M, Cowie MR, Tavazzi L, et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 2017;19:1414-23
   PubMedGoogle Scholar
• Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21:S212-20
   PubMed Web of Science ®Google Scholar
• Thorvaldsen T, Benson L, Dahlström U, et al. Use of evidence-based therapy and survival in heart failure in Sweden 2003–2012. Eur J Heart Fail 2016;18:503-11
   PubMed Web of Science ®Google Scholar
• Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007;28:42-51
   PubMed Web of Science ®Google Scholar
• Eriksen BO, Stefansson VT, Jenssen TG, et al. Blood pressure and age-related GFR decline in the general population. BMC Nephrol 2017;18:77
   PubMedGoogle Scholar
• Ford E, Adams J, Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open 2012;2:e001094
   PubMed Web of Science ®Google Scholar
• Colquitt JL, Mendes D, Clegg AJ, et al. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess 2014;18:1-560
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81
   PubMed Web of Science ®Google Scholar
• Luo J, Brunelli SM, Jensen DE, et al. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol 2016;11:90-100
   PubMed Web of Science ®Google Scholar
• Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33
   PubMed Web of Science ®Google Scholar
• Office for National Statistics [Internet]. National life tables, UK: 2013–2015. London, UK: ONS; 2016. Available at: https://www.ons.gov.uk/releases/nationallifeexpectancytablesuk2013to2015 [Last accessed 8 December 2016]
   Google Scholar
• Curtis L. Personal Social Services Research Unit (PSSRU) unit costs of health and social care 2015. Canterbury, UK: PSSRU; 2015. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2015/ [Last accessed 8 December 2016]
   Google Scholar
• Haymarket Media Group Ltd. Monthly index of medical specialities. London, UK: MIMS; 2017. Available at: http://www.mims.co.uk/ [Last accessed 16 November 2017]
   Google Scholar
• Göhler A, Geisler BP, Manne JM, et al. Utility estimates for decision-analytic modeling in chronic heart failure–health states based on New York Heart Association classes and number of rehospitalizations. Value Health 2009;12:185-7
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Heidelberg New York London: Springer Open; 2014
   Google Scholar
• Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2012;34:1404-13
   PubMedGoogle Scholar
• Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7
   PubMed Web of Science ®Google Scholar
• Cohn, JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Levy WC, Crane BA, et al. Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am J Cardiol 2004;94:1577-80
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure. Circulation 2004;109:1594-602
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005;11:91-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods [PMG9]. London, UK: NICE; 2013. Available at: https://www.nice.org.uk/process/pmg9 [Last accessed 6 December 2017]
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667-77
   PubMed Web of Science ®Google Scholar
• Schmidt S, Ditting T, Deutsch B, et al. Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. J Nephrol 2015;28:165-72
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222-31
   PubMed Web of Science ®Google Scholar
• Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 2015;17:1050-6
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-21
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015;17:1057-65
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015;314:151-61
   PubMed Web of Science ®Google Scholar